Royan Stem Cell Technology’s New Trial Tests Mesenchymal Stromal Cells for Stroke
The Phase 1 study will assess the safety and feasibility of giving donor umbilical cord cells after a procedure to remove a blood clot in people with acute ischemic stroke.

Royan Stem Cell Technology Company is sponsoring ARTEMIS, a Phase 1 trial of Whartocell, a therapy made from donor umbilical cord mesenchymal stromal cells, in adults with acute ischemic stroke.
Researchers will compare standard stroke care with standard care plus the cell therapy after mechanical thrombectomy, a procedure to remove the clot and restore blood flow. The trial will assess safety and feasibility and track neurological outcomes during follow-up.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
- Sponsor: Royan Stem Cell Technology Company
- Phase/Status: Phase 1; Not yet recruiting
- Indication: Acute ischemic stroke in 10 adults aged 18–70 years, with imaging-confirmed stroke, NIHSS score of 6–20, prestroke mRS below 2, eligibility for mechanical thrombectomy within six hours of symptom onset, and successful reperfusion defined as mTICI grade 2b–3.
- Arms/Dosing: Allogeneic umbilical cord-derived mesenchymal stromal cells: a single dose of 20 × 10⁶ cells suspended in 20 mL of normal saline, administered through a microcatheter into the artery supplying the infarcted area following successful reperfusion after mechanical thrombectomy.
- Control: Standard stroke care, including mechanical thrombectomy, followed by routine post-thrombectomy care and physical rehabilitation according to the study protocol.
- Endpoints: Primary: serious adverse events during the intervention and at 1 hour, 24 hours, 3 days, 7 days, 1 month, 3 months, and 6 months after the intervention; adverse events during the same time windows; and feasibility, measured as the proportion of intervention-group participants in whom the planned infusion is successfully completed, during the intervention (Day 0). Secondary: proportion with mRS 0–2 at baseline, 24 hours, 3 days, 7 days, and 1, 3, and 6 months; change in NIHSS from baseline at those same time points.
- Timing: Study start: November 20, 2026 (estimated); primary completion: November 20, 2027 (estimated); study completion: June 20, 2028 (estimated).
- Contact: Elaheh Khodadoust, MD-MPH — elaheh.khodadoust@gmail.com, +989121216987; Masoumeh Nouri, PhD — mnouritra@gmail.com, +989129582158201; Supervisor of Interventional Cath Lab — dr.f.ebrahimnia@gmail.com, 02182141000.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Mesenchymal Stem Cell Extracellular Vesicles Reprogram Microglia and Prevent Neurodegeneration in Alzheimer’s Models
Kangstem Biotech Reports Positive Phase 2a Results for Stem Cell Knee Osteoarthritis Therapy
CellFiber Opens First International Subsidiary in Philadelphia to Support Cell and Gene Therapy Development
Evia Bio Announces Availability of GMP-Grade DMSO-Free Cryopreservation Media for Mesenchymal Stromal Cells
Porton Advanced Announces FDA Acceptance of Drug Master File for Umbilical Cord Stem Cell-Derived Exosomes
INmune Bio and Uniphar Team Up to Support International Access to Umbilical Cord-Derived Cell Therapy for RDEB







